Kura Oncology (KURA) Non-Current Deffered Revenue (2024 - 2026)

Kura Oncology (KURA) has 3 years of Non-Current Deffered Revenue data on file, last reported at $416.7 million in Q1 2026.

• Quarterly Non-Current Deffered Revenue rose 53.26% year-over-year to $416.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $416.7 million (up 53.26% YoY) and the FY2025 annual result came in at $424.9 million, up 67.35% from the prior year.
• Non-Current Deffered Revenue slipped to $416.7 million in Q1 2026 per KURA's latest filing, from $424.9 million in the prior quarter.
• Across five years, Non-Current Deffered Revenue topped out at $424.9 million in Q4 2025 and bottomed at $252.5 million in Q2 2025.
• The 3-year median for Non-Current Deffered Revenue is $270.4 million (2025), against an average of $314.8 million.
• The widest annual swing landed in 2025, when Non-Current Deffered Revenue soared 67.35%; it then surged 53.26% in 2026.
• Tracing KURA's Non-Current Deffered Revenue over 3 years: stood at $253.9 million in 2024, then soared by 67.35% to $424.9 million in 2025, then fell by 1.92% to $416.7 million in 2026.
• Per Business Quant, the three latest KURA Non-Current Deffered Revenue figures stand at $416.7 million (Q1 2026), $424.9 million (Q4 2025), and $268.9 million (Q3 2025).

Peer Comparison